Court green-lights Clo­vis case af­ter de­tail­ing ev­i­dence the board ‘ig­nored red flags’ on false safe­ty and ef­fi­ca­cy da­ta

11 months ago
R&D

‘There are mo­ments’: Sanofi’s new CEO is think­ing through the R&D strat­e­gy — and on­col­o­gy will be key

11 months ago
Bioregnum

Biotechs are spend­ing record sums on R&D — should that wor­ry you at least a lit­tle?

12 months ago
R&D

A mi­cro­cap biotech salves old wounds with pos­i­tive PhII re­port on sta­tus epilep­ti­cus, but plen­ty of ques­tions re­main

12 months ago
R&D

Ver­tex buys the top spot on the list of the biggest pre­clin­i­cal M&A deals. Were they robbed or was it a steal?

Last year
Deals

Worst. biotech. deal. ever? Turns out Ab­b­Vie has plen­ty of com­pe­ti­tion for that ti­tle

Last year
Deals
R&D

We­bi­nar: Re­al World End­points — the brave new world com­ing in build­ing fran­chise ther­a­pies

Last year
Regulatory

Bay­er’s $240M up­front for Blue­Rock ac­qui­si­tion puts them in the high rollers club for pre­clin­i­cal biotech buy­outs

Last year
Deals
Discovery

No­var­tis' $18.5B in M&A un­der Vas Narasimhan says a lot about their care­ful — but op­por­tunis­tic — deal strat­e­gy

Last year
Deals

What makes Hal Bar­ron tick? Look at the peo­ple he’s team­ing up with at GSK

Last year
People
Bioregnum

As Take­da ab­sorbs Shire’s R&D ops, the fo­cus is on re­plac­ing a cen­tral­ized com­mand mod­el with a ‘light touch’ in a re­struc­tured glob­al or­ga­ni­za­tion

Last year
Deals
R&D

H1 analy­sis: The high-stakes ta­ble in the biotech deals casi­no is pay­ing out some record-set­ting win­nings

Last year
Deals

The top 15 mega-deals in bio­phar­ma: Ab­b­Vie and Bris­tol-My­ers ac­qui­si­tions stir fresh de­bate over what's too big to buy

Last year
Deals

Gene ther­a­py R&D deals turn red hot as Big Phar­ma steps up to play

Last year
Deals
Cell/Gene Tx

Bio­phar­ma BD teams are speed­ing in­to the fast lane — cash in hand — as deal­mak­ing con­tin­ues to heat up in Q1 of­fen­sive

Last year
Pharma

The top 50 biotechs by mar­ket cap — and what their CEOs’ com­pen­sa­tion deals tell us about bio­phar­ma

Last year
People

The BC­MA fren­zy: Track­ing the 37 drugs around the world rac­ing to over­take blue­bird bio and Cel­gene

Last year
R&D

Top 5 Chi­nese play­ers: What does Ever­est's land­mark deal with Im­munomedics say about the flur­ry of in-li­cens­ing to Chi­na?

Last year
China

Go­ing gang­busters: The top 20 biotech plat­form deals by up­front cash

Last year
Pharma

An­oth­er play­er in the gene ther­a­py field is gun­ning for the Duchenne MD crown — and here’s what they're bet­ting on

Last year
Bioregnum
Cell/Gene Tx

The top 20 pre­clin­i­cal biotech deals ranked by cash up­front re­veals 3 big play­ers — and some ma­jor league stinkers

Last year
Deals
Discovery

Top 20 can­cer drug deals: As­traZeneca just changed the glob­al land­scape for deal­mak­ing in on­col­o­gy

Last year
Pharma

The top 10 Alzheimer's deals tell us a lot about a big change of di­rec­tion for a dis­as­ter-prone field

Last year
R&D
Pharma

Team build­ing. Pipeline re­vamp. For­ward thrust. What does a decade of deals at Gilead tell us about Daniel O’Day’s first M&A moves?

Last year
Pharma
First page Previous page 123456 Next page Last page